Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Weight gain is one of the most challenging issues in patients with schizophrenia treated with antipsychotics. Several meta-analyses have been conducted to review the efficacy of topiramate in reducing weight, however, several issues regarding the methodology had arisen of which make the results remain ambiguous. Methods: We conducted a meta-analysis of randomised controlled trials about the use of topiramate in patients with schizophrenia for weight reduction. Ten double-blinded randomised placebo-controlled trials and seven open-label randomised controlled trials included 905 patients. Results: Patients treated with topiramate experienced a greater reduction in body weight and BMI. Patients in countries of the lower overweight population showed more significant BMI reduction. Besides, studies from the Middle East and South Asia showed the greatest effect in body weight change, followed by East Asia, then Europe/America. Topiramate group was outperformed control group with significant psychopathology improvement. No difference between two groups regarding the overall side effects. Conclusions: Topiramate was significantly superior to control group in mitigating weight gain and psychopathology in antipsychotic-treated patients with schizophrenia. The effects of topiramate augmentation need further investigations in larger definitive studies using methodological rigor and thorough assessments.

Original languageEnglish
Pages (from-to)1-19
Number of pages19
JournalInternational Journal of Psychiatry in Clinical Practice
DOIs
Publication statusAccepted/In press - Mar 20 2018

Fingerprint

Antipsychotic Agents
Weight Gain
Meta-Analysis
Schizophrenia
Randomized Controlled Trials
Far East
Psychopathology
Control Groups
Body Weight Changes
Middle East
topiramate
Weight Loss
Placebos
Body Weight
Weights and Measures
Population

Keywords

  • antipsychotics
  • obesity
  • overweight
  • schizophrenia
  • Topiramate

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{9390e767d8014419ab63828675e57456,
title = "Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials",
abstract = "Objective: Weight gain is one of the most challenging issues in patients with schizophrenia treated with antipsychotics. Several meta-analyses have been conducted to review the efficacy of topiramate in reducing weight, however, several issues regarding the methodology had arisen of which make the results remain ambiguous. Methods: We conducted a meta-analysis of randomised controlled trials about the use of topiramate in patients with schizophrenia for weight reduction. Ten double-blinded randomised placebo-controlled trials and seven open-label randomised controlled trials included 905 patients. Results: Patients treated with topiramate experienced a greater reduction in body weight and BMI. Patients in countries of the lower overweight population showed more significant BMI reduction. Besides, studies from the Middle East and South Asia showed the greatest effect in body weight change, followed by East Asia, then Europe/America. Topiramate group was outperformed control group with significant psychopathology improvement. No difference between two groups regarding the overall side effects. Conclusions: Topiramate was significantly superior to control group in mitigating weight gain and psychopathology in antipsychotic-treated patients with schizophrenia. The effects of topiramate augmentation need further investigations in larger definitive studies using methodological rigor and thorough assessments.",
keywords = "antipsychotics, obesity, overweight, schizophrenia, Topiramate",
author = "Goh, {Kah Kheng} and Chen, {Chun Hsin} and Lu, {Mong Liang}",
year = "2018",
month = "3",
day = "20",
doi = "10.1080/13651501.2018.1449864",
language = "English",
pages = "1--19",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia

T2 - meta-analysis of randomised controlled trials

AU - Goh, Kah Kheng

AU - Chen, Chun Hsin

AU - Lu, Mong Liang

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Objective: Weight gain is one of the most challenging issues in patients with schizophrenia treated with antipsychotics. Several meta-analyses have been conducted to review the efficacy of topiramate in reducing weight, however, several issues regarding the methodology had arisen of which make the results remain ambiguous. Methods: We conducted a meta-analysis of randomised controlled trials about the use of topiramate in patients with schizophrenia for weight reduction. Ten double-blinded randomised placebo-controlled trials and seven open-label randomised controlled trials included 905 patients. Results: Patients treated with topiramate experienced a greater reduction in body weight and BMI. Patients in countries of the lower overweight population showed more significant BMI reduction. Besides, studies from the Middle East and South Asia showed the greatest effect in body weight change, followed by East Asia, then Europe/America. Topiramate group was outperformed control group with significant psychopathology improvement. No difference between two groups regarding the overall side effects. Conclusions: Topiramate was significantly superior to control group in mitigating weight gain and psychopathology in antipsychotic-treated patients with schizophrenia. The effects of topiramate augmentation need further investigations in larger definitive studies using methodological rigor and thorough assessments.

AB - Objective: Weight gain is one of the most challenging issues in patients with schizophrenia treated with antipsychotics. Several meta-analyses have been conducted to review the efficacy of topiramate in reducing weight, however, several issues regarding the methodology had arisen of which make the results remain ambiguous. Methods: We conducted a meta-analysis of randomised controlled trials about the use of topiramate in patients with schizophrenia for weight reduction. Ten double-blinded randomised placebo-controlled trials and seven open-label randomised controlled trials included 905 patients. Results: Patients treated with topiramate experienced a greater reduction in body weight and BMI. Patients in countries of the lower overweight population showed more significant BMI reduction. Besides, studies from the Middle East and South Asia showed the greatest effect in body weight change, followed by East Asia, then Europe/America. Topiramate group was outperformed control group with significant psychopathology improvement. No difference between two groups regarding the overall side effects. Conclusions: Topiramate was significantly superior to control group in mitigating weight gain and psychopathology in antipsychotic-treated patients with schizophrenia. The effects of topiramate augmentation need further investigations in larger definitive studies using methodological rigor and thorough assessments.

KW - antipsychotics

KW - obesity

KW - overweight

KW - schizophrenia

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=85044205169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044205169&partnerID=8YFLogxK

U2 - 10.1080/13651501.2018.1449864

DO - 10.1080/13651501.2018.1449864

M3 - Article

AN - SCOPUS:85044205169

SP - 1

EP - 19

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

ER -